Oral GnRH antagonists, which include elagolix, relugolix, and linzagolix, signify a substantial progression, providing rapid and reversible suppression of ovarian hormone synthesis with dose-dependent effects and enhanced convenience. Innovative treatment modalities that target nonhormonal mechanisms, such as extracellular matrix remodeling, angiogenesis, and gene modulation, provide promising prospects for future uterus-sparing interventions. This narrative review evaluates the current and advancing landscape of medical therapies for uterine fibroids, presenting evidence-based perspectives to inform clinical decision-making within an increasingly personalized therapeutic context.

14 days ago

Review • Journal

PGR (Progesterone receptor)

Orgovyx (relugolix) • Yselty (linzagolix)

27d

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (clinicaltrials.gov)

P2, N=60, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting

27 days ago

Enrollment open

Eligard (leuprolide acetate) • Nubeqa (darolutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix)

CAMO959A12103: A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSMA-positive prostate cancer that has spread to other parts of the body.athway inhibitor (ARPI) in adults with PSMA-positive prostate cancer that has spread to other parts of the body. (2025-521859-23-00)

P1/2, N=61, Not yet recruiting, Novartis Pharma AG

1 month ago

New P1/2 trial

Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Firmagon (degarelix) • Orgovyx (relugolix)

REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermediate-Risk Prostate Cancer: a Special Focus on Quality of Life and Erectile Function Recovery (2025-521170-33-00)

P1/2, N=50, Recruiting, IRCCS Istituto Nazionale Tumori Fondazione Pascale | Not yet recruiting --> Recruiting

1 month ago

Enrollment open • HEOR

Orgovyx (relugolix)

RELAX: Relugolix for Endometriosis Associated Pain (clinicaltrials.gov)

P=N/A, N=33, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

1 month ago

New trial • Real-world evidence

Orgovyx (relugolix)

2ms

REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov)

P2, N=94, Active, not recruiting, Emory University | Trial completion date: Dec 2025 --> Oct 2026

2 months ago

Trial completion date

Orgovyx (relugolix) • leuprolide acetate for depot suspension

3ms

APEX: Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)

P2, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Jan 2026 --> Jan 2027

3 months ago

Trial primary completion date

Xtandi (enzalutamide) • Eligard (leuprolide acetate) • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix)

3ms

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial (clinicaltrials.gov)

P2, N=30, Recruiting, Mayo Clinic | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Jul 2026 --> Dec 2026

3 months ago

Trial completion date • Trial primary completion date

Orgovyx (relugolix)

3ms

Insights in Endocervical Mucus Secretion (clinicaltrials.gov)

P4, N=15, Recruiting, Oregon Health and Science University | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Jan 2026

3 months ago

Enrollment open • Trial initiation date

Orgovyx (relugolix)

3ms

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (clinicaltrials.gov)

P2, N=532, Recruiting, Mayo Clinic | N=220 --> 532

3 months ago

Enrollment change

Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension

4ms

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov)

P2, N=25, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Nov 2028 | Trial primary completion date: Jan 2027 --> Nov 2028

4 months ago

Enrollment closed • Trial completion date • Trial primary completion date

docetaxel • Xtandi (enzalutamide) • Nubeqa (darolutamide) • apalutamide • triptorelin • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension

4ms

Case Report: Cutaneous metastatic mucin-producing prostate adenocarcinoma. (PubMed, Front Oncol)

He was started on androgen deprivation therapy with relugolix...It also raises awareness of prostate cancer presenting as solitary cutaneous metastasis and calls attention to the potential value of PSA screening in select elderly patients. Recognizing uncommon cutaneous manifestations may lead to earlier diagnosis and improved management of advanced internal malignancies.

4 months ago

Journal

NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8) • NKX3-1 (NK3 homeobox 1)

Orgovyx (relugolix)